Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Insulin: Drug formulations

Jonathan M Zand, PharmD BCPS
Section Editor
David M Nathan, MD
Deputy Editor
Jean E Mulder, MD

Insulin used in the treatment of patients with diabetes mellitus is available in recombinant human (insulin NPH, regular insulin) and recombinant analog (aspart, glulisine, lispro, detemir, degludec, glargine) drug formulations; each formulation has unique pharmacokinetic properties (ie, differing onset and duration of action). Some formulations are available in more than one concentration (U-100, which is 100 units per mL and more concentrated forms, ie, U-200 [200 units per mL], U-300 [300 units per mL], or U-500 [500 units per mL]), which may also affect the onset and duration of action. The more concentrated forms are available, when needed, to control hyperglycemia in severely insulin-resistant patients. Links to the Lexicomp drug information topics are provided below.

For indications for clinical use, properties, and additional information on specific agents, refer to the relevant UpToDate topics.


Injectable insulin

Rapid-acting insulin

Insulin aspart (NovoLOG U-100, NovoRapid U-100)

Insulin aspart: Drug information

Insulin aspart: Pediatric drug information

Insulin aspart: Patient drug information


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Tue Nov 15 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.